The UK is facing an unprecedented wave of medicine shortages, with pharmacists warning of risks to patient health. Tiffany Brewer, Senior Director of Global Industry Strategy – Life Sciences at Blue Yonder, explores why old models of supply chain planning are no longer enough and how technology transformation can deliver resilience.
According to a government briefing published in April, the UK has been experiencing ‘shortages of medicines used to treat diabetes, attention deficit hyperactivity disorder (ADHD) and epilepsy, hormone replacement therapy (HRT) and others’. These shortages are not isolated incidents but symptoms of deeper fragilities in the pharmaceutical supply chain.
New research from Community Pharmacy England highlights the scale of the crisis. It found that 95% of pharmacy teams are currently experiencing supply issues, with 73% warning these shortages are putting patient health at serious risk. The situation, described as a ‘distressing new normal for community pharmacies and their patients alike’, underscores how systemic weaknesses have been building for years.
While the UK is not alone in experiencing disruption, it faces unique pressures. Brexit has exacerbated supply problems, creating barriers to the free movement of medicines. A study by the Nuffield Trust last year was blunt in its assessment: ‘products no longer flow as smoothly across the borders with the EU and in the long-term our struggles to approve as many medicines might mean we have fewer alternatives available’.
Compounding this, there are fresh geopolitical risks. There is widespread anticipation that President Trump will impose tariffs on global pharmaceutical imports from August 1. If enacted, these tariffs would reverberate far beyond US borders, with knock-on effects across the UK.
Evaluating the risks
This is about more than Brexit or domestic logistics. Global pharmaceutical supply chains are tightly interlinked and shocks in one region quickly cascade worldwide. Countries such as Ireland, Germany, India and Switzerland are among those most exposed to tariffs, but they are also critical suppliers to the UK. If trade policy in the US drives up production costs or squeezes margins on generic drugs, the fallout could include scaled-back manufacturing, delayed shipments and reduced availability across multiple regions.
Pharmaceutical supply chains are especially ill-equipped to respond rapidly. Unlike other sectors, companies cannot simply switch suppliers or relocate production lines overnight. Regulatory requirements mean every new supplier must be vetted, approved and brought into compliance – a process that can take years. This structural rigidity leaves the industry vulnerable to geopolitical shocks and patients vulnerable to treatment delays.
Critical supply nodes are particularly at risk. Active pharmaceutical ingredients (APIs) and raw materials sourced from China and India are tariff-sensitive and when packaging components and outsourced manufacturing are factored in, vulnerabilities multiply.
Coping strategies
Faced with these challenges, pharmaceutical businesses are rethinking their sourcing strategies. Nearshoring – relocating manufacturing operations closer to end markets – is attracting renewed interest. With incentives such as US tax credits and EU-led reshoring programmes, regional production is becoming a realistic option.
Nearshoring has clear advantages. Shorter supply routes reduce transport costs and lead times, while proximity to markets enables quicker responses to demand shifts. Most importantly, regionalised production strengthens resilience at a time when geopolitical and environmental disruptions are becoming more frequent.
But practical barriers remain. Higher labour costs, shortages of skilled manufacturing talent and limited contract manufacturing capacity all make it harder to justify investment, particularly for high-volume or low-margin drugs.
Technology as the enabler
With so many variables in play, traditional planning is no longer enough. The sector requires real-time visibility, predictive modelling and scenario planning to anticipate and address supply vulnerabilities.
The goal is to assess the impact of a potential tariff change or simulate the effects of nearshore production within hours rather than weeks. Without these capabilities, every disruption – from tariffs to transport delays – becomes a guessing game.
The next frontier is not just visibility but actionability. Modern platforms must support fast, autonomous decision-making, enabling pharmaceutical organisations to course-correct in real-time. Automation is vital here, bridging operational gaps, controlling labour costs and reducing the risk of human error, all while ensuring compliance remains front and centre.
The most advanced supply chain platforms have moved beyond passive dashboards. They enable autonomous decisions based on live data, transforming operations from reactive firefighting to proactive scenario-based planning. In a heavily regulated sector such as pharmaceuticals, this shift could prove transformative.
A new model for resilience
Medicine shortages are not a temporary disruption but a sign that old models of supply chain planning no longer work. The volatility of global markets, from Brexit fallout to potential tariffs, makes clear that the question is not if further shocks will occur, but how fast companies can adapt.
Pharmaceutical firms equipped with real-time intelligence, predictive modelling and autonomous capabilities will not only withstand volatility – they will set the benchmark for resilient, patient-centred care.
The path forward lies in embracing technology transformation as a core strategy, not an add-on. Those that act now will help ensure patients in the UK and beyond continue to receive the treatments they need, even in an unpredictable global environment.
